LPL Financial LLC Acquires 38,412 Shares of Elanco Animal Health Incorporated $ELAN

LPL Financial LLC grew its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 23.8% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 199,595 shares of the company’s stock after buying an additional 38,412 shares during the period. LPL Financial LLC’s holdings in Elanco Animal Health were worth $2,096,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of the stock. Freestone Grove Partners LP bought a new position in Elanco Animal Health in the fourth quarter worth approximately $20,396,000. Dimensional Fund Advisors LP lifted its holdings in shares of Elanco Animal Health by 6.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 17,900,987 shares of the company’s stock worth $216,774,000 after purchasing an additional 1,074,274 shares in the last quarter. Adage Capital Partners GP L.L.C. grew its position in Elanco Animal Health by 148.8% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 1,741,308 shares of the company’s stock valued at $21,087,000 after purchasing an additional 1,041,308 shares during the period. DDD Partners LLC grew its position in Elanco Animal Health by 202.7% in the 1st quarter. DDD Partners LLC now owns 1,492,992 shares of the company’s stock valued at $15,676,000 after purchasing an additional 999,716 shares during the period. Finally, Shapiro Capital Management LLC increased its stake in Elanco Animal Health by 7.5% during the 4th quarter. Shapiro Capital Management LLC now owns 12,356,702 shares of the company’s stock valued at $149,640,000 after purchasing an additional 862,900 shares in the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Stock Down 1.0%

Shares of NYSE:ELAN opened at $17.5250 on Wednesday. Elanco Animal Health Incorporated has a 1 year low of $8.02 and a 1 year high of $18.08. The company has a market capitalization of $8.71 billion, a PE ratio of 20.38, a price-to-earnings-growth ratio of 3.29 and a beta of 1.66. The business has a fifty day moving average price of $14.87 and a two-hundred day moving average price of $12.35. The company has a debt-to-equity ratio of 0.61, a current ratio of 2.60 and a quick ratio of 1.40.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Thursday, August 7th. The company reported $0.26 EPS for the quarter, topping analysts’ consensus estimates of $0.20 by $0.06. The company had revenue of $1.24 billion for the quarter, compared to analysts’ expectations of $1.19 billion. Elanco Animal Health had a return on equity of 7.04% and a net margin of 9.68%.The business’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same period in the previous year, the business posted $0.30 EPS. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. Analysts forecast that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on ELAN shares. Piper Sandler raised their price objective on shares of Elanco Animal Health from $12.00 to $18.00 and gave the company a “neutral” rating in a research note on Monday, August 11th. Leerink Partners raised shares of Elanco Animal Health from a “market perform” rating to an “outperform” rating and set a $18.00 price target on the stock in a research report on Thursday, July 17th. William Blair upgraded Elanco Animal Health from a “market perform” rating to an “outperform” rating in a research note on Thursday, June 26th. Leerink Partnrs raised Elanco Animal Health from a “hold” rating to a “strong-buy” rating in a research note on Thursday, July 17th. Finally, UBS Group raised their target price on Elanco Animal Health from $18.00 to $19.00 and gave the company a “buy” rating in a report on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $17.33.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.